GNB1L抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06321(GNB1L Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P06321(GNB1L Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The GNB1L (G Protein Subunit Beta 1 Like) gene, located on chromosome 22q11.2. encodes a protein belonging to the WD-repeat G protein β-subunit family. Though structurally similar to Gβ proteins, GNB1L lacks conserved residues critical for G protein signaling, suggesting divergent functions. It is implicated in 22q11.2 deletion syndrome (DiGeorge syndrome), where haploinsufficiency contributes to congenital heart defects, neurodevelopmental disorders, and psychiatric conditions. GNB1L interacts with chromatin remodelers and transcription factors, influencing neural and cardiac development.

Antibodies targeting GNB1L are primarily used in research to study its expression patterns, subcellular localization, and molecular interactions. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence. Studies using these antibodies have revealed GNB1L's nuclear and cytoplasmic distribution, with roles in transcriptional regulation and protein scaffolding. Dysregulation of GNB1L is linked to CHARGE syndrome, autism spectrum disorders, and schizophrenia, highlighting its clinical relevance.

Current research focuses on clarifying GNB1L's mechanistic contributions to developmental pathways and its potential as a biomarker. However, functional insights remain limited, necessitating further exploration of its interactome and post-translational modifications. Commercial GNB1L antibodies vary in specificity; validation using knockout controls is essential to ensure reliability in experimental models.